8-K: Coya Therapeutics Completes Patient Enrollment in ALSTARS Trial

Coya Therapeutics announced the full enrollment of 120 patients in its Phase 2/3 ALSTARS trial for ALS treatment, with topline data expected in early Q2 2027.

Summary

• Coya Therapeutics, Inc. has announced the completion of patient enrollment for its Phase 2/3 ALSTARS Trial (NCT07161999).
• The trial is evaluating COYA 302, a combination therapy for amyotrophic lateral sclerosis (ALS).
• A total of 120 patients were planned for enrollment, and additional participants in screening may also be enrolled if eligible.
• Topline data from the double-blind treatment phase are anticipated in early Q2 2027.
• The ALSTARS Trial is a randomized, multi-center, double-blind, placebo-controlled study.
• Participants will be randomized 1:1:1 to receive one of two COYA 302 dosing regimens or a placebo for a 24-week double-blind treatment phase.
• Patients completing the initial phase can enter a 24-week blinded active-treatment extension phase, allowing for up to 48 weeks of data on COYA 302.
• The primary endpoint is the change in disease severity over time, measured by the ALSFRS-R total score from baseline to Week 24.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, indicating progress in a critical clinical trial for a promising ALS treatment.

Positives

• Full enrollment of 120 patients in the Phase 2/3 ALSTARS Trial has been achieved, a significant milestone for the ALS treatment candidate.
• The trial design includes an extension phase, allowing for up to 48 weeks of data collection on COYA 302.
• The company anticipates topline data in early Q2 2027, providing a clear timeline for investors.
• COYA 302 has received FDA Fast Track designation, which may expedite the development and review process.

Negatives

• The primary endpoint is based on a 24-week treatment phase, and the full efficacy and safety profile will be determined over a longer period.
• The trial is placebo-controlled, meaning a significant portion of patients will not receive the active treatment during the initial phase.

Risks

• The actual results of clinical trials may differ from the Company's expectations.
• The Company's ability to advance its product candidates through clinical development processes is subject to various risks and uncertainties.
• Future results of operations and financial position, including cash runway, are subject to known and unknown risks and uncertainties.
• The events or circumstances referred to in forward-looking statements may not occur due to known and unknown risks and uncertainties.

Future Outlook

Topline data from the double-blind treatment phase of the ALSTARS Trial are anticipated in early Q2 2027. The company expects to advance its product candidates through development and is focused on the potential therapeutic benefits and economic value of its product candidates.

Management Comments

• Forward-looking statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties.

Industry Context

StockSavvy.ai notes that the full enrollment in a Phase 2/3 trial for ALS is a significant step for Coya Therapeutics. ALS is a devastating neurodegenerative disease with limited treatment options, making any progress in clinical trials highly scrutinized by the industry and patient advocacy groups.

Stakeholder Impact

• Shareholders: Positive impact due to progress in a key clinical trial, potentially increasing the value of the company.
• Patients and Families: Hope for a new treatment option for ALS, a disease with significant unmet medical needs.
• Medical Community: Interest in the efficacy and safety data of COYA 302 as it progresses through clinical development.

Next Steps

• Continue the double-blind treatment phase of the ALSTARS Trial.
• Collect and analyze data from the 24-week treatment phase and the subsequent extension phase.
• Release topline data from the double-blind treatment phase in early Q2 2027.

Key Dates

Recommendation

The completion of patient enrollment is a positive step, but the actual efficacy and safety data are still pending. Investors should hold to await topline results in early Q2 2027 before making further decisions.

Keywords

ALS, Amyotrophic Lateral Sclerosis, COYA 302, Clinical Trial, Phase 2/3, ALSTARS Trial, Neurology, Drug Development